Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pimavanserin Tartrate

FDA-approved product (tablet, oral), marketed as Nuplazid, Pimavanserin.

Registered studies
46
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Pimavanserin Tartrate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hallucinations
  • Parkinson disease
  • Psychosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antipsychotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli45.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

46registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pimavanserin Tartrate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pimavanserin Tartrate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

    NCT04373317 · start 2022-10-24

    Registered record
    Registry ID
    NCT04373317
    Conditions
    Parkinson's Disease Psychosis
    Interventions
    Pimavanserin; Quetiapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-10-24
    Completion
    2028-08-24
    Enrolment
    358

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease Psychosis
    InterventionPimavanserin; Quetiapine
    PhasePhase 4
    Registry statusRecruiting

  • Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

    NCT05523895 · start 2022-08-09

    Registered record
    Registry ID
    NCT05523895
    Conditions
    Irritability Associated With Autism Spectrum Disorder
    Interventions
    Pimavanserin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2022-08-09
    Completion
    2024-09-27
    Enrolment
    237

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritability Associated With Autism Spectrum Disorder
    InterventionPimavanserin; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Comparing Antipsychotic Medications in LBD Over Time

    NCT05590637 · start 2022-04-22

    Registered record
    Registry ID
    NCT05590637
    Conditions
    Parkinson's Disease Psychosis; Dementia With Lewy Bodies
    Interventions
    Pimavanserin; Quetiapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2022-04-22
    Completion
    2027-02
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease Psychosis; Dementia With Lewy Bodies
    InterventionPimavanserin; Quetiapine
    PhasePhase 4
    Registry statusRecruiting

  • Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

    NCT03947216 · start 2020-10-23

    Registered record
    Registry ID
    NCT03947216
    Conditions
    Parkinson Disease
    Interventions
    Active drug: pimavanserin 17mg (2 strength tablets); Placebo: 2 tablets containing same excipients except active compound; Assessment of severity of ICD (impulse control disorders); Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors; Assessment of quality of life; Assessment of depression; Assessment of cognition; Assessment of severity of Parkinson Disease; Blood analysis; Cardiac monitoring
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2020-10-23
    Completion
    2024-06-17
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionActive drug: pimavanserin 17mg (2 strength tablets); Placebo: 2 tablets containing same excipients except active compound; Assessment of severity of ICD (impulse control disorders); Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors +6 more
    PhasePhase 2
    Registry statusCompleted

  • Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

    NCT04531982 · start 2020-08-05

    Registered record
    Registry ID
    NCT04531982
    Conditions
    Schizophrenia
    Interventions
    Pimavanserin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-08-05
    Completion
    2024-02-19
    Enrolment
    454

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPimavanserin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

    NCT04292223 · start 2020-02-10

    Registered record
    Registry ID
    NCT04292223
    Conditions
    Parkinson Disease Psychosis
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-02-10
    Completion
    2022-04-26
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease Psychosis
    InterventionPimavanserin
    PhasePhase 4
    Registry statusCompleted

  • Pimavanserin for Insomnia In Veterans With Posttraumatic Stress Disorder

    NCT04188392 · start 2020-01-06

    Registered record
    Registry ID
    NCT04188392
    Conditions
    Post-traumatic Stress Disorder; Insomnia
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-01-06
    Completion
    2021-11-10
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-traumatic Stress Disorder; Insomnia
    InterventionPimavanserin
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

    NCT04164758 · start 2019-10-23

    Registered record
    Registry ID
    NCT04164758
    Conditions
    Parkinson's Disease
    Interventions
    Pimavanserin; Placebo; Quetiapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2019-10-23
    Completion
    2020-09-25
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionPimavanserin; Placebo; Quetiapine
    PhasePhase 2
    Registry statusTerminated

  • Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

    NCT04000009 · start 2019-06-06

    Registered record
    Registry ID
    NCT04000009
    Conditions
    Adjunctive Treatment of Major Depressive Disorder
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2019-06-06
    Completion
    2021-02-22
    Enrolment
    235

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdjunctive Treatment of Major Depressive Disorder
    InterventionPimavanserin
    PhasePhase 3
    Registry statusTerminated

  • Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

    NCT03968159 · start 2019-04-25

    Registered record
    Registry ID
    NCT03968159
    Conditions
    Adjunctive Treatment of Major Depressive Disorder
    Interventions
    Pimavanserin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-04-25
    Completion
    2020-05-29
    Enrolment
    298

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdjunctive Treatment of Major Depressive Disorder
    InterventionPimavanserin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Pimavanserin Treatment in TS

    NCT04794413 · start 2018-11-12

    Registered record
    Registry ID
    NCT04794413
    Conditions
    Tourette Syndrome; Tardive Dyskinesia
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-11-12
    Completion
    2021-02-28
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTourette Syndrome; Tardive Dyskinesia
    InterventionPimavanserin
    PhaseEarly phase 1
    Registry statusCompleted

  • Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    NCT03623321 · start 2018-07-17

    Registered record
    Registry ID
    NCT03623321
    Conditions
    Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-07-17
    Completion
    2023-05-05
    Enrolment
    595

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuropsychiatric Symptoms Related to Neurodegenerative Disease
    InterventionPimavanserin
    PhasePhase 3
    Registry statusCompleted

  • A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

    NCT03575052 · start 2018-05-21

    Registered record
    Registry ID
    NCT03575052
    Conditions
    Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Interventions
    Pimavanserin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-05-21
    Completion
    2022-05-06
    Enrolment
    784

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuropsychiatric Symptoms Related to Neurodegenerative Disease
    InterventionPimavanserin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

    NCT03482882 · start 2018-03-09

    Registered record
    Registry ID
    NCT03482882
    Conditions
    Treatment of Depression in Adults With Parkinson's Disease (PD)
    Interventions
    Pimavanserin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-03-09
    Completion
    2019-07-24
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment of Depression in Adults With Parkinson's Disease (PD)
    InterventionPimavanserin
    PhasePhase 2
    Registry statusCompleted

  • Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

    NCT03325556 · start 2017-09-27

    Registered record
    Registry ID
    NCT03325556
    Conditions
    Dementia-related Psychosis
    Interventions
    Placebo; Pimavanserin 34 mg; Pimavanserin 20 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-09-27
    Completion
    2019-10-30
    Enrolment
    392

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDementia-related Psychosis
    InterventionPlacebo; Pimavanserin 34 mg; Pimavanserin 20 mg
    PhasePhase 3
    Registry statusCompleted